StocksMedium•6 October 2026•
1 min read
ArriVent Stock Plummets 60% Following Clinical Trial Failure
Key Facts
1ArriVent stock dropped 60% after a clinical trial missed its primary endpoint.
ArriVent stock dropped 60% after a clinical trial missed its primary endpoint. Investing.com reported that ArriVent Biopharma shares experienced a massive sell-off following the announcement that its lead candidate or specific therapy failed to reach its primary objective.
The clinical failure has undermined investor confidence in the drug's path toward regulatory approval. This sharp decline in valuation occurred as broader market sentiment remained sensitive to economic shifts, with US Consumer Confidence previously reported at 81.9 on September 29, 2026.